Weesp, Netherlands

Tinka Tuinstra


 


Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2007-2011

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Tinka Tuinstra: Innovator in Pharmaceutical Chemistry

Introduction

Tinka Tuinstra is a notable inventor based in Weesp, Netherlands. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds that target human ORL1 receptors. With a total of 3 patents to her name, her work is paving the way for advancements in medical treatments.

Latest Patents

Tuinstra's latest patents include innovative compounds such as benzimidazolone and quinazolinone derivatives that act as agonists on human ORL1 receptors. These inventions focus on a group of novel derivatives that can be utilized in pharmaceutical compositions for treating disorders associated with ORL1 receptors. Another significant patent involves hydronopol substituted benzimidazolone and quinazolinone derivatives, which also serve as agonists on human ORL1 receptors. Both patents emphasize the preparation of these compounds and their potential therapeutic applications.

Career Highlights

Tinka Tuinstra is currently associated with Solvay Pharmaceuticals B.V., where she continues to explore and develop innovative pharmaceutical solutions. Her work has been instrumental in advancing the understanding of ORL1 receptor interactions and their implications in various medical conditions.

Collaborations

Throughout her career, Tuinstra has collaborated with esteemed colleagues such as Herman H Van Stuivenberg and Jacobus A J Den Hartog. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Tinka Tuinstra's contributions to pharmaceutical chemistry are noteworthy, particularly her innovative work on ORL1 receptor agonists. Her patents reflect a commitment to advancing medical science and improving treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…